Matt’s Take

Matt's Take Matthew Herper

STAT Plus: Over-the-counter Sudafed PE doesn’t work. Neither does our system for evaluating older drugs

Matt's Take Matthew Herper

STAT Plus: What past blockbusters can tell us about future of Wegovy and other weight loss medicines

Matt's Take Matthew Herper

STAT Plus: From drug shortages to high prices, U.S. system’s shortcomings have deep roots

Matt's Take Matthew Herper

STAT Plus: Francis deSouza’s tenure at Illumina is a lesson in how not to handle CEO succession

Matt's Take Matthew Herper

STAT Plus: Battle for the soul of Illumina is also a referendum on its CEO

Matt's Take Matthew Herper

STAT Plus: Bernie Sanders’ accidentally great drug pricing idea

Special Report Matthew Herper

STAT Plus: Here’s why we’re not prepared for the next wave of biotech innovation

Matt's Take Matthew Herper

STAT Plus: If a new Alzheimer’s drug works, was there any point to the Aduhelm controversy? Yes

Matt's Take Matthew Herper

Don’t let shrill debates keep you from getting a Covid booster

Matt's Take Matthew Herper

STAT Plus: Why Illumina has a merger mess of its own making

Matt's Take Matthew Herper

STAT Plus: Moderna’s suing Pfizer? Wow! OK, now take a deep breath.

Matt's Take Matthew Herper

STAT Plus: The Senate’s drug pricing bill is an inevitable solution. It will still have plenty of unintended consequences

Matt's Take Matthew Herper

STAT Plus: Can we really get better Covid vaccines? There are big hurdles, but some hope

Matt's Take Matthew Herper

New Covid trial results may point toward better ways to study medicines

Matt's Take Matthew Herper

STAT Plus: Gilead’s Dan O’Day is pharma’s most charming executive — but with his deals falling apart, charm may not be enough

Matt's Take Matthew Herper

STAT Plus: The fall of Eric Lander and the end of science’s ‘big ego’ era

Matt's Take Matthew Herper

STAT Plus: Why Biogen’s Medicare mess is bad for the pharmaceutical industry

Matt's Take Matthew Herper

STAT Plus: Robert Califf is a fervent believer in data. At the FDA, will that be enough?

Matt's Take Matthew Herper

The Biden administration wants scientific advisers. It just doesn’t like what they have to say

Matt's Take Matthew Herper

STAT Plus: By approving Biogen’s Alzheimer’s drug, the FDA is shifting its rules. That is a giant risk

Matt's Take Matthew Herper

Having pandemic panic attacks about virus variants? National preparation is the cure

Matt's Take Matthew Herper

Biden’s plan to end policy of keeping Covid vaccine doses in reserve is the first step in a difficult journey

Matt's Take Matthew Herper

Antibody drugs seem to work. But the virus is moving faster than we can make them

Matt's Take Matthew Herper

The lesson from Trump catching Covid-19: With this virus, there are no magic bullets

Matt's Take Matthew Herper

STAT Plus: Eager for a Covid vaccine, Trump now trusts drug companies he previously vilified

Matt's Take Matthew Herper

STAT Plus: People are dying from coronavirus because we’re not fast enough at clinical research

Matt's Take Matthew Herper

The U.S. gets a D- in the coronavirus fight. That stands for ‘disorganization,’ and it’s fixable

Matt's Take Matthew Herper

Coronavirus testing is starting to get better — but it has a long way to go

Matt's Take Matthew Herper

Why Trump’s coronavirus speech, designed to calm, deepened panic